Cybin Inc. (CYBN) 10-Year Financial Performance & Capital Metrics

CYBN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutCybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Show more

Revenue $0
EBITDA -$143M -81.6%
Net Income -$113M -44.9%
EPS (Diluted) -0.61 +93.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -42.76% -0.8%
ROIC -115.81% -3.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-56.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM-921.18%

ROCE

10Y Avg-340.77%

5Y Avg-489.46%

3Y Avg-53.34%

Latest-54.11%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Jul 2017	Jul 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	864K	0	0	0	0
Revenue Growth %	-	-	-	-	-1%	-	-	-
Cost of Goods Sold+	0	0	0	664K	168K	251K	424K	0
COGS % of Revenue	-	-	-	0.77%	-	-	-	-
Gross Profit+	0	0	0	200K	-168K	-251K	-424K	0
Gross Margin %	-	-	-	0.23%	-	-	-	-
Gross Profit Growth %	-	-	-	-	-1.84%	-0.49%	-0.69%	1%
Operating Expenses+	127.22K	80.52K	1.94M	30.72M	63.84M	51.52M	78.84M	143.15M
OpEx % of Revenue	-	-	-	35.56%	-	-	-	-
Selling, General & Admin	127.22K	80.52K	1.63M	26.52M	46.25M	25.37M	46.47M	88.24M
SG&A % of Revenue	-	-	-	30.69%	-	-	-	-
Research & Development	0	0	321.6K	3.3M	17.59M	26.14M	32.36M	54.91M
R&D % of Revenue	-	-	-	3.82%	-	-	-	-
Other Operating Expenses	0	0	0	-482K	0	0	0	0
Operating Income+	-127K	-80.52K	-1.95M	-31.04M	-63.84M	-51.52M	-78.84M	-143.15M
Operating Margin %	-	-	-	-35.92%	-	-	-	-
Operating Income Growth %	-	0.37%	-23.27%	-14.88%	-1.06%	0.19%	-0.53%	-0.82%
EBITDA+	-127K	80.62K	0	-30.99M	-63.67M	-51.28M	-78.58M	-142.67M
EBITDA Margin %	-	-	-	-35.86%	-	-	-	-
EBITDA Growth %	-	1.63%	-1%	-	-1.05%	0.19%	-0.53%	-0.82%
D&A (Non-Cash Add-back)	0	161.14K	1.95M	49K	168K	233K	260K	475K
EBIT	0	0	-1.95M	-32.21M	-63.84M	-51.52M	-78.84M	-143.15M
Net Interest Income+	0	0	0	50K	0	603K	619K	8.29M
Interest Income	0	0	0	60K	241K	603K	619K	8.29M
Interest Expense	0	0	0	10K	241K	0	0	0
Other Income/Expense	4	-20K	9.6K	-1.7M	-3.79M	4.03M	756K	30.01M
Pretax Income+	-127K	-101K	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M	-113.14M
Pretax Margin %	-	-	-	-37.29%	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.06%	0.84%	1%	1%
Net Income+	-127K	-101K	-1.94M	-32.22M	-71.42M	-40.04M	-78.08M	-113.14M
Net Margin %	-	-	-	-37.29%	-	-	-	-
Net Income Growth %	-	0.2%	-18.25%	-15.57%	-1.22%	0.44%	-0.95%	-0.45%
Net Income (Continuing)	-127K	-101K	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M	-113.14M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.01	-0.04	-999999.00	-0.43	-0.22	-9.41	-0.61
EPS Growth %	-	-	-	-999999%	1%	0.49%	-41.77%	0.94%
EPS (Basic)	-0.01	-0.01	-0.05	-999999.00	-0.43	-0.22	-9.50	-0.61
Diluted Shares Outstanding	13.89M	13.89M	49.98M	10	167.29M	185.43M	185.43M	185.43M
Basic Shares Outstanding	13.89M	13.89M	40.5M	10	167.29M	185.43M	185.43M	185.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Jul 2017	Jul 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	433.08K	318.38K	1.64M	1.64M	66.48M	58.35M	218.54M	165.97M
Cash & Short-Term Investments	432.81K	314.32K	1.54M	1.54M	64.03M	53.64M	208.99M	135.02M
Cash Only	432.81K	314.32K	1.54M	1.54M	64.03M	53.64M	208.99M	135.02M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	74K	1.33M	2.1M	3.05M	0	5.88M
Days Sales Outstanding	-	-	-	561.44	-	-	-	-
Inventory	0	0	0	0	-212K	1.27M	0	0
Days Inventory Outstanding	-	-	-	0	-	1.85K	-	-
Other Current Assets	263	4.06K	0	0	1.34M	1.77M	2.18M	2.91M
Total Non-Current Assets+	10K	90K	71K	71K	25.63M	25.71M	83.49M	92.65M
Property, Plant & Equipment	0	0	0	557K	557K	491K	547K	141K
Fixed Asset Turnover	-	-	-	1.55x	-	-	-	-
Goodwill	0	0	0	23.37M	23.37M	22.89M	47.48M	51.49M
Intangible Assets	0	0	0	1.7M	1.7M	2.08M	35.47M	41.02M
Long-Term Investments	0	0	71K	71K	242K	242K	0	0
Other Non-Current Assets	10K	90K	0	-25.63M	-242K	0	0	0
Total Assets+	443.08K	408.38K	1.71M	1.71M	92.11M	84.06M	302.02M	258.62M
Asset Turnover	-	-	-	0.50x	-	-	-	-
Asset Growth %	-	-0.08%	3.19%	0%	52.84%	-0.09%	2.59%	-0.14%
Total Current Liabilities+	150.29K	13.65K	263K	263K	4.9M	7.91M	10.1M	21.42M
Accounts Payable	0	0	263K	2.79M	5.26M	5.66M	9.8M	21.42M
Days Payables Outstanding	-	-	-	1.54K	11.43K	8.24K	8.44K	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	150.29K	13.65K	0	2.11M	-362K	2.25M	291K	0
Current Ratio	2.88x	23.32x	6.24x	6.24x	13.57x	7.38x	21.65x	7.75x
Quick Ratio	2.88x	23.32x	6.24x	6.24x	13.61x	7.22x	21.65x	7.75x
Cash Conversion Cycle	-	-	-	-973.87	-	-	-	-
Total Non-Current Liabilities+	0	0	0	1.09M	1.09M	5.26M	0	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	1.09M	0	0	0	0
Total Liabilities	150.29K	13.65K	263K	263K	5.99M	7.91M	10.1M	21.42M
Total Debt+	0	0	0	0	0	0	291K	0
Net Debt	-432.81K	-314.32K	-1.54M	-1.54M	-64.03M	-53.64M	-208.99M	-135.02M
Debt / Equity	-	-	-	-	-	-	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-3.90x	-	-	-	-	-	-
Interest Coverage	-	-	-	-3103.50x	-264.89x	-	-	-
Total Equity+	292.78K	394.73K	1.45M	1.45M	86.12M	76.16M	291.93M	237.2M
Equity Growth %	-	0.35%	2.67%	0%	58.47%	-0.12%	2.83%	-0.19%
Book Value per Share	0.02	0.03	0.03	144784.07	0.51	0.41	1.57	1.28
Total Shareholders' Equity	292.78K	394.73K	1.45M	1.45M	86.12M	76.16M	291.93M	237.2M
Common Stock	420K	721.38K	2.19M	2.19M	100.68M	141.45M	443.88M	464.36M
Retained Earnings	-127.22K	-448.75K	-810K	-810K	-33.03M	-100.66M	-226.23M	-339.37M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	64	24K	24K	-366K	62.53M	-7.23M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Jul 2017	Jul 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	2.81K	-83.78K	-1.39K	-19.03M	-19.03M	-45.21M	-68.91M	-101.3M
Operating CF Margin %	-	-	-	-22.02%	-	-	-	-
Operating CF Growth %	-	-30.77%	0.98%	-13738.89%	0%	-1.38%	-0.52%	-0.47%
Net Income	-127.22K	-100.52K	-1.94K	-32.22M	-32.22M	-67.63M	-78.08M	-113.14M
Depreciation & Amortization	0	0	0	49K	49K	168K	424K	475K
Stock-Based Compensation	0	0	154	11.55M	18.03M	4.69M	13.89M	42.87M
Deferred Taxes	0	0	0	898K	898K	0	0	0
Other Non-Cash Items	0	20K	631	1.96M	1.96M	4.01M	-111K	-21.71M
Working Capital Changes	130.03K	-3.26K	-226	-1.27M	-1.27M	213K	-5.03M	-9.79M
Change in Receivables	0	0	-178	-1.49M	-1.49M	-773K	-1.09M	-1.41M
Change in Inventory	0	0	0	-511K	-511K	0	0	0
Change in Payables	0	0	0	0	0	0	0	0
Cash from Investing+	-10K	-35K	-170	-1.19M	-1.19M	-770K	6.92M	-1.97M
Capital Expenditures	-10K	-35K	0	-231K	-231K	-520K	-21	-1.97M
CapEx % of Revenue	-	-	-	0.27%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	-170	-96	250K	-3.17K	-709.98K	0
Cash from Financing+	440K	0	5.26K	82.72M	35.78M	35.78M	254.51M	20.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	440K	0	5.26K	6.49M	35.78M	362K	56K	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.19K	-118.78K	-1.39K	-19.26M	-19.26M	-45.73M	-69.62M	-103.27M
FCF Margin %	-	-	-	-22.29%	-	-	-	-
FCF Growth %	-	-15.53%	0.99%	-13905.7%	0%	-1.37%	-0.52%	-0.48%
FCF per Share	-0.00	-0.01	-0.00	-999999.00	-0.12	-0.25	-0.38	-0.56
FCF Conversion (FCF/Net Income)	-0.02x	0.83x	0.00x	0.59x	0.27x	1.13x	0.88x	0.90x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-43.38%	-29.38%	-210.99%	-2225.14%	-163.13%	-49.35%	-42.43%	-42.76%
Return on Invested Capital (ROIC)	-	-	-	-	-435.36%	-173.24%	-111.83%	-115.81%
Gross Margin	-	-	-	23.15%	-	-	-	-
Net Margin	-	-	-	-3729.17%	-	-	-	-
Debt / Equity	-	-	-	-	-	-	0.00x	-
Interest Coverage	-	-	-	-3103.50x	-264.89x	-	-	-
FCF Conversion	-0.02x	0.83x	0.00x	0.59x	0.27x	1.13x	0.88x	0.90x
Revenue Growth	-	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Cybin Inc. (CYBN) grew revenue by 0.0% over the past year. Growth has been modest.

Cybin Inc. (CYBN) reported a net loss of $122.9M for fiscal year 2025.

Dividend & Returns

Cybin Inc. (CYBN) has a return on equity (ROE) of -42.8%. Negative ROE indicates the company is unprofitable.

Cybin Inc. (CYBN) had negative free cash flow of $105.6M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Cybin Inc. (CYBN) 10-Year Financial Performance & Capital Metrics

CYBN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$143M -81.6%
Net Income -$113M -44.9%
EPS (Diluted) -0.61 +93.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -42.76% -0.8%
ROIC -115.81% -3.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-56.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM-921.18%

ROCE

10Y Avg-340.77%

5Y Avg-489.46%

3Y Avg-53.34%

Latest-54.11%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Jul 2017	Jul 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	864K	0	0	0	0
Revenue Growth %	-	-	-	-	-1%	-	-	-
Cost of Goods Sold+	0	0	0	664K	168K	251K	424K	0
COGS % of Revenue	-	-	-	0.77%	-	-	-	-
Gross Profit+	0	0	0	200K	-168K	-251K	-424K	0
Gross Margin %	-	-	-	0.23%	-	-	-	-
Gross Profit Growth %	-	-	-	-	-1.84%	-0.49%	-0.69%	1%
Operating Expenses+	127.22K	80.52K	1.94M	30.72M	63.84M	51.52M	78.84M	143.15M
OpEx % of Revenue	-	-	-	35.56%	-	-	-	-
Selling, General & Admin	127.22K	80.52K	1.63M	26.52M	46.25M	25.37M	46.47M	88.24M
SG&A % of Revenue	-	-	-	30.69%	-	-	-	-
Research & Development	0	0	321.6K	3.3M	17.59M	26.14M	32.36M	54.91M
R&D % of Revenue	-	-	-	3.82%	-	-	-	-
Other Operating Expenses	0	0	0	-482K	0	0	0	0
Operating Income+	-127K	-80.52K	-1.95M	-31.04M	-63.84M	-51.52M	-78.84M	-143.15M
Operating Margin %	-	-	-	-35.92%	-	-	-	-
Operating Income Growth %	-	0.37%	-23.27%	-14.88%	-1.06%	0.19%	-0.53%	-0.82%
EBITDA+	-127K	80.62K	0	-30.99M	-63.67M	-51.28M	-78.58M	-142.67M
EBITDA Margin %	-	-	-	-35.86%	-	-	-	-
EBITDA Growth %	-	1.63%	-1%	-	-1.05%	0.19%	-0.53%	-0.82%
D&A (Non-Cash Add-back)	0	161.14K	1.95M	49K	168K	233K	260K	475K
EBIT	0	0	-1.95M	-32.21M	-63.84M	-51.52M	-78.84M	-143.15M
Net Interest Income+	0	0	0	50K	0	603K	619K	8.29M
Interest Income	0	0	0	60K	241K	603K	619K	8.29M
Interest Expense	0	0	0	10K	241K	0	0	0
Other Income/Expense	4	-20K	9.6K	-1.7M	-3.79M	4.03M	756K	30.01M
Pretax Income+	-127K	-101K	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M	-113.14M
Pretax Margin %	-	-	-	-37.29%	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.06%	0.84%	1%	1%
Net Income+	-127K	-101K	-1.94M	-32.22M	-71.42M	-40.04M	-78.08M	-113.14M
Net Margin %	-	-	-	-37.29%	-	-	-	-
Net Income Growth %	-	0.2%	-18.25%	-15.57%	-1.22%	0.44%	-0.95%	-0.45%
Net Income (Continuing)	-127K	-101K	-1.94M	-32.22M	-67.63M	-47.49M	-78.08M	-113.14M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.01	-0.04	-999999.00	-0.43	-0.22	-9.41	-0.61
EPS Growth %	-	-	-	-999999%	1%	0.49%	-41.77%	0.94%
EPS (Basic)	-0.01	-0.01	-0.05	-999999.00	-0.43	-0.22	-9.50	-0.61
Diluted Shares Outstanding	13.89M	13.89M	49.98M	10	167.29M	185.43M	185.43M	185.43M
Basic Shares Outstanding	13.89M	13.89M	40.5M	10	167.29M	185.43M	185.43M	185.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Jul 2017	Jul 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	433.08K	318.38K	1.64M	1.64M	66.48M	58.35M	218.54M	165.97M
Cash & Short-Term Investments	432.81K	314.32K	1.54M	1.54M	64.03M	53.64M	208.99M	135.02M
Cash Only	432.81K	314.32K	1.54M	1.54M	64.03M	53.64M	208.99M	135.02M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	74K	1.33M	2.1M	3.05M	0	5.88M
Days Sales Outstanding	-	-	-	561.44	-	-	-	-
Inventory	0	0	0	0	-212K	1.27M	0	0
Days Inventory Outstanding	-	-	-	0	-	1.85K	-	-
Other Current Assets	263	4.06K	0	0	1.34M	1.77M	2.18M	2.91M
Total Non-Current Assets+	10K	90K	71K	71K	25.63M	25.71M	83.49M	92.65M
Property, Plant & Equipment	0	0	0	557K	557K	491K	547K	141K
Fixed Asset Turnover	-	-	-	1.55x	-	-	-	-
Goodwill	0	0	0	23.37M	23.37M	22.89M	47.48M	51.49M
Intangible Assets	0	0	0	1.7M	1.7M	2.08M	35.47M	41.02M
Long-Term Investments	0	0	71K	71K	242K	242K	0	0
Other Non-Current Assets	10K	90K	0	-25.63M	-242K	0	0	0
Total Assets+	443.08K	408.38K	1.71M	1.71M	92.11M	84.06M	302.02M	258.62M
Asset Turnover	-	-	-	0.50x	-	-	-	-
Asset Growth %	-	-0.08%	3.19%	0%	52.84%	-0.09%	2.59%	-0.14%
Total Current Liabilities+	150.29K	13.65K	263K	263K	4.9M	7.91M	10.1M	21.42M
Accounts Payable	0	0	263K	2.79M	5.26M	5.66M	9.8M	21.42M
Days Payables Outstanding	-	-	-	1.54K	11.43K	8.24K	8.44K	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	150.29K	13.65K	0	2.11M	-362K	2.25M	291K	0
Current Ratio	2.88x	23.32x	6.24x	6.24x	13.57x	7.38x	21.65x	7.75x
Quick Ratio	2.88x	23.32x	6.24x	6.24x	13.61x	7.22x	21.65x	7.75x
Cash Conversion Cycle	-	-	-	-973.87	-	-	-	-
Total Non-Current Liabilities+	0	0	0	1.09M	1.09M	5.26M	0	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	1.09M	0	0	0	0
Total Liabilities	150.29K	13.65K	263K	263K	5.99M	7.91M	10.1M	21.42M
Total Debt+	0	0	0	0	0	0	291K	0
Net Debt	-432.81K	-314.32K	-1.54M	-1.54M	-64.03M	-53.64M	-208.99M	-135.02M
Debt / Equity	-	-	-	-	-	-	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-3.90x	-	-	-	-	-	-
Interest Coverage	-	-	-	-3103.50x	-264.89x	-	-	-
Total Equity+	292.78K	394.73K	1.45M	1.45M	86.12M	76.16M	291.93M	237.2M
Equity Growth %	-	0.35%	2.67%	0%	58.47%	-0.12%	2.83%	-0.19%
Book Value per Share	0.02	0.03	0.03	144784.07	0.51	0.41	1.57	1.28
Total Shareholders' Equity	292.78K	394.73K	1.45M	1.45M	86.12M	76.16M	291.93M	237.2M
Common Stock	420K	721.38K	2.19M	2.19M	100.68M	141.45M	443.88M	464.36M
Retained Earnings	-127.22K	-448.75K	-810K	-810K	-33.03M	-100.66M	-226.23M	-339.37M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	64	24K	24K	-366K	62.53M	-7.23M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Jul 2017	Jul 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	2.81K	-83.78K	-1.39K	-19.03M	-19.03M	-45.21M	-68.91M	-101.3M
Operating CF Margin %	-	-	-	-22.02%	-	-	-	-
Operating CF Growth %	-	-30.77%	0.98%	-13738.89%	0%	-1.38%	-0.52%	-0.47%
Net Income	-127.22K	-100.52K	-1.94K	-32.22M	-32.22M	-67.63M	-78.08M	-113.14M
Depreciation & Amortization	0	0	0	49K	49K	168K	424K	475K
Stock-Based Compensation	0	0	154	11.55M	18.03M	4.69M	13.89M	42.87M
Deferred Taxes	0	0	0	898K	898K	0	0	0
Other Non-Cash Items	0	20K	631	1.96M	1.96M	4.01M	-111K	-21.71M
Working Capital Changes	130.03K	-3.26K	-226	-1.27M	-1.27M	213K	-5.03M	-9.79M
Change in Receivables	0	0	-178	-1.49M	-1.49M	-773K	-1.09M	-1.41M
Change in Inventory	0	0	0	-511K	-511K	0	0	0
Change in Payables	0	0	0	0	0	0	0	0
Cash from Investing+	-10K	-35K	-170	-1.19M	-1.19M	-770K	6.92M	-1.97M
Capital Expenditures	-10K	-35K	0	-231K	-231K	-520K	-21	-1.97M
CapEx % of Revenue	-	-	-	0.27%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	-170	-96	250K	-3.17K	-709.98K	0
Cash from Financing+	440K	0	5.26K	82.72M	35.78M	35.78M	254.51M	20.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	440K	0	5.26K	6.49M	35.78M	362K	56K	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.19K	-118.78K	-1.39K	-19.26M	-19.26M	-45.73M	-69.62M	-103.27M
FCF Margin %	-	-	-	-22.29%	-	-	-	-
FCF Growth %	-	-15.53%	0.99%	-13905.7%	0%	-1.37%	-0.52%	-0.48%
FCF per Share	-0.00	-0.01	-0.00	-999999.00	-0.12	-0.25	-0.38	-0.56
FCF Conversion (FCF/Net Income)	-0.02x	0.83x	0.00x	0.59x	0.27x	1.13x	0.88x	0.90x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-43.38%	-29.38%	-210.99%	-2225.14%	-163.13%	-49.35%	-42.43%	-42.76%
Return on Invested Capital (ROIC)	-	-	-	-	-435.36%	-173.24%	-111.83%	-115.81%
Gross Margin	-	-	-	23.15%	-	-	-	-
Net Margin	-	-	-	-3729.17%	-	-	-	-
Debt / Equity	-	-	-	-	-	-	0.00x	-
Interest Coverage	-	-	-	-3103.50x	-264.89x	-	-	-
FCF Conversion	-0.02x	0.83x	0.00x	0.59x	0.27x	1.13x	0.88x	0.90x
Revenue Growth	-	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Cybin Inc. (CYBN) grew revenue by 0.0% over the past year. Growth has been modest.

Cybin Inc. (CYBN) reported a net loss of $122.9M for fiscal year 2025.

Dividend & Returns

Cybin Inc. (CYBN) has a return on equity (ROE) of -42.8%. Negative ROE indicates the company is unprofitable.

Cybin Inc. (CYBN) had negative free cash flow of $105.6M in fiscal year 2025, likely due to heavy capital investments.